Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A NEW drug therapy for diabetes treatment is currently being developed by an international research team led by WA scientists, which combines an existing anti-diabetic drug with bile acids to improve the drug's delivery and prolong release.
Lead researcher and PhD candidate from Curtin University's Biotechnology and Drug Development Research Laboratory, Armin Mooranian, says that every five minutes someone is diagnosed with prediabetes or diabetes in Australia, resulting in billions of dollars spent on complications and treatment.
"Currently, the anti-diabetic drugs we have on the market are limited by their poor ability to exert complete control and treat symptoms and complications of diabetes," he says.
"Low drug absorption, which results in unnecessary add-on therapies and higher dose administration, and failure to restore bile acid disturbances in the gut are further limitations of current anti-diabetic drug therapies."
As such, the researchers utilised a well-known anti-diabetic drug, gliclazide (G)—used to treat type-2 diabetes by regulating glucose levels—mixed with the bile acid deoxycholic acid (DCA), a metabolic by-product of intestinal bacteria naturally produced in humans.
http://www.sciencewa.net.au/topics/health-a-medicine/item/3298-progress-in-diabetes-drug-delivery
Lead researcher and PhD candidate from Curtin University's Biotechnology and Drug Development Research Laboratory, Armin Mooranian, says that every five minutes someone is diagnosed with prediabetes or diabetes in Australia, resulting in billions of dollars spent on complications and treatment.
"Currently, the anti-diabetic drugs we have on the market are limited by their poor ability to exert complete control and treat symptoms and complications of diabetes," he says.
"Low drug absorption, which results in unnecessary add-on therapies and higher dose administration, and failure to restore bile acid disturbances in the gut are further limitations of current anti-diabetic drug therapies."
As such, the researchers utilised a well-known anti-diabetic drug, gliclazide (G)—used to treat type-2 diabetes by regulating glucose levels—mixed with the bile acid deoxycholic acid (DCA), a metabolic by-product of intestinal bacteria naturally produced in humans.
http://www.sciencewa.net.au/topics/health-a-medicine/item/3298-progress-in-diabetes-drug-delivery